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Development of HPV-associated cancers not only depends on efficient negative regulation of cell cycle control that
supports the accumulation of genetic damage, but also relies on immune evasion that enable the virus to go
undetected for long periods of time. In this way, HPV-related tumors usually present MHC class I down-regulation,
impaired antigen-processing ability, avoidance of T-cell mediated killing, increased immunosuppression due to Treg
infiltration and secrete immunosuppressive cytokines. Thus, these are the main obstacles that immunotherapy has
to face in the treatment of HPV-related pathologies where a number of different strategies have been developed to
overcome them including new adjuvants. Although antigen-specific immunotherapy induced by therapeutic HPV
vaccines was proved extremely efficacious in pre-clinical models, its progression through clinical trials suffered
poor responses in the initial trials. Later attempts seem to have been more promising, particularly against the
well-defined precursors of cervical, anal or vulvar cancer, where the local immunosuppressive milieu is less active.
This review focuses on the advances made in these fields, highlighting several new technologies (such as mRNA
vaccine, plant-derived vaccine). The most promising immunotherapies used in clinical trials are also summarized,
along with integrated strategies, particularly promising in controlling tumor metastasis and in eliminating cancer
cells altogether.
After the early promising clinical results, the development of therapeutic HPV vaccines need to be implemented
and applied to the users in order to eradicate HPV-associated malignancies, eradicating existing perception (after
the effectiveness of commercial preventive vaccines) that we have already solved the problem.
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Cervical cancer is the third most common cancer in
women and the fifth most common overall cancer
worldwide as age standardized incidence rate in both
sexes combined [1]. The prime causal factor of the dis-
ease is a persistent infection with high-risk human papil-
lomavirus (HPV), with individuals failing to mount a
sufficient immune response against the virus. The high-
risk HPV genome encodes three oncoproteins, E5, E6
and E7, the last two oncoproteins are constitutively
expressed in high-grade lesions and cancer, and are re-
quired for the onset and maintenance of the malignant* Correspondence: venuti@ifo.it
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unless otherwise stated.phenotype. About 170 HPV genotypes have been iden-
tified and 40 can infect the ano-genital area: uterine
cervix, vulva, vaginal wall, penis and anus. HPVs are
classified as high-risk types, commonly associated with
cancer, and low-risk, mostly identified in condyloma
acuminatum. The International Agency for Research on
Cancer (IARC) conducted a study on over 30,000 cer-
vical cancers that showed HPV 16, 18, 58, 33, 45, 31, 52,
35, 59, 39, 51, 56, to be the most common types asso-
ciated with invasive cervical cancer with HPV 16 ac-
counting for over 50% and HPV 16 and 18 for >70%
worldwide [2]. Epidemiological data report that HPV in-
fection occurs at least once during lifespan in about 75%
of U.S. women [3], and natural history shows that most
HPV infections resolve spontaneously, while in some
women infection persists and progresses to cervical can-
cer. The incidence of high-grade cervical intraepithelial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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grade CIN, and without treatment about one third pro-
gresses to cervical cancer [4,5].
Cervical carcinogenesis is a multi-step process, which
starts with viral infection and requires the establishment
of persistent HPV infection. Papillomavirus persistence is
favored by at least three major factors: the virus life cycle
that takes place away from dermal immune cells, the ab-
sence of virus-induced cell lysis with, in turn, no or weak
inflammatory response and finally the altered immune re-
sponse induced by viral proteins. Thus, cancer develop-
ment depends not only on efficient negative regulation of
cell cycle control supporting the accumulation of genetic
damage, but also on immune evasion that enables the
virus to lie undetected for a long time. Many studies con-
firm that persistent HPV infection is the most important
risk factor, mainly with high-risk subtypes [5]. Studies in
HIV women or in patients treated with immunosup-
pressive agents reported an increased incidence of CIN
lesions, suggesting an important role of cell-mediated im-
mune response against HPV antigens [6,7]. The role of
systemic and local mucosal immune responses to HPV
antigens is controversial. Some studies suggest a positive
association between systemic cell-mediated immune re-
sponses and the regression of CIN [8]. Moreover, antibody
responses to the major viral capsid protein, L1, can be
detected by about 6 months after infection and may be
observed up to 5 years later in women who have been
cleared from infection. Type specific L1 antibody re-
sponses have also been detected in persistent disease and
cancer in about half of the patients [9,10].
A number of escape factors may affect the natural im-
mune response against HPV proteins, together with the
loss of correct signals from immune system to activate
adaptive immune system. Indeed, optimal activation of
adaptive immunity and generation of specific CD4 T
helper 1 type immunity supporting development of CD8
cytotoxic T cells against viral early proteins, like E2, E6,
E7, is critical for virus clearance in basal epithelial cells.
T helper cells also support optimal activation of B cells,
with secreting HPV capsid type specific neutralizing
antibodies, which can protect against subsequent infec-
tions at mucosal and systemic levels [11]. Spontaneous
regression mainly occurs in lesions infiltrated by CD4+
and cytotoxic CD8+ T cells and it is also associated with
circulating HPV early antigen-specific CD4+ and CD8+
T cells, which also have a favorable prognostic signifi-
cance [12-15].
In the early phases of carcinogenesis the three onco-
genes of the virus E5, E6 and E7 play an important role
in immune evasion. In particular, the E5 protein [16]
seems to further facilitate the virus-induced immune
escape by down-regulating MHC/HLA class I and II
[17,18] and inducing a reduction in recognizing CD8+ Tcells, at least in vitro [19]. This down regulation does not
affect the HLA molecules (HLA-C/E) whose presence on
the cell surface to avoid natural killer action is essential
[20,21]. Several pieces of experimental evidence show that
neither synthesis nor transport to the cell surface of HLA-
C/E is affected by E5 expression, leading to the conclusion
that E5 selectively inhibits surface expression of HLA-A
and HLA-B [17]. In this manner, high risk HPVs are po-
tentially capable of avoiding both CTL and NK cell killing,
favoring persistent infection. In the late phases, when inte-
gration of the virus (frequently with loss of E2 and E5
genes) into the host genome blocks the productive life cell
cycle, favoring immortalization and mutation acquisition,
the E6 and E7 still play a fundamental role: i) high-risk E6
reduces the surface expression of CDH1 by epithelial cells;
ii) E6 and E7 inhibit the transcription of toll-like receptor
(TLR) 9, necessary to activate antigen-presenting cells as
part of innate immune response; iii) E7 reduces expres-
sion of transporter associated with antigen processing 1
(TAP1), a component of the presentation and processing
pathway, so blocking the activation of specific T lympho-
cytes; iv) high-risk HPVs down-regulates the expression of
pro-inflammatory cytokines [22].
In addition, therapeutic T cell effector mechanisms are
limited due to the following: changes in local immunity;
the production of cytokines such as Interleukin (IL)-10 or
transforming growth factor (TGF-beta); increased number
of regulatory T cells (Tregs) and to immunosuppressive
myeloid cells that are commonly observed in HPV related
cancers. Moreover, frequent mutational events in cancer
include HLA loss of expression, with subsequent escape
of tumor cells [23,24].
In this manner, HPV-related tumors usually present
MHC class I down-regulation, impaired antigen-pro-
cessing ability, avoidance of T-cell mediated killing, in-
creased immunosuppression due to Treg infiltration,
and secrete immunosuppressive cytokines [25].
These are the main obstacles faced when achieving a
valid immunotherapy against HPV-related pathologies
where a number of different strategies have been devel-
oped in order to overcome them including adjuvants.
Adjuvant is a term derived from the Latin word, adju-
vare, which means to aid or to help. Historical boosting
humoral immune response was the goal of the devel-
oped adjuvants and, as a result, many commonly used
adjuvants are effective in elevating serum antibody titers,
but do not elicit significant Th1 responses or cytotoxic
T lymphocytes (CTLs). However, certain adjuvants have
recently been demonstrated to be able to induce cellular
immunity which are summarized in Table 1 according to
their mechanism of action [26].
Conceptually, immunity can be utilized in a thera-
peutic setting in two ways: first, by using specific natural
o synthetic antibodies against defined targets, or second,
Table 1 List of adjuvants by their dominant mechanism of action
Antigen delivery systems Immunopotentiators
• Electroporation • Alternative pathogen-associated molecular patterns (PAMPs): e.g. Cholera enterotoxin;
liquenase.
• Gene gun • Heat-shock proteins
• Liposomes • Lysosome and endocelllular reticulum (ER) targeting agents
• Virosomes™ • Saponins (Quils, QS-21)
• ISCOMSW • TLRs agonists: e.g, imiquimod, oligonucleotides (CpG, etc.), double-stranded RNA (dsRNA)
• Micro/Nanoparticles: e.g. microparticles of poly
(lactide-co-glycolide) (PLG)
• Cytokines & chemokines: e.g. IL2, IL12 and GM-CSF
• Emulsions: e.g., MF59, Montanides • Treg inactivators: e.g. anti-apoptotic molecules, low-dose cyclophosphamide,
antibodies anti-CD 25, -CTLA, -IL10, or -PDL-1
• Virus-like particles & viral/bacterial vectors • Monophosphoryl lipid A (MPL) and synthetic derivates
• Muramyl dipeptide (MDP) and derivatives
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specific antigens (preventive and therapeutic vaccines). In
particular, for HPV-induced lesions and cancer viral anti-
gens or/and virus-induced host antigens can be targeted
by these approaches. Indeed, once a patient is infected
with HPV there is no effective way to cure persistent HPV
infection which is the first step towards the development
of pre-cancerous lesions. It was estimated that even with
mass vaccination through commercially highly effective
preventive quadrivalent or bivalent HPV vaccines [27-31],
it will take at least 20 years before the incidence and
prevalence of cervical cancer significantly decreases due to
the slow rate of carcinogenesis. Furthermore, during this
period of time many people will be infected by high risk
HPV that will consequently increase the burden of estab-
lished HPV infections and HPV-associated diseases that
lie undetected, untreated and slowly progressing toward
malignant transformation.
Thus, there is great need for the development of novel
therapeutic intervention to control HPV-associated dis-
ease and cancers. Given that existing treatments [32-34]
are partially effective in cancers or pre-neoplastic le-
sions, and useless in persistent infections, immune the-
rapies may represent a valid tool.
The following paragraphs summarize these issues and
focus on the treatment (clinical trials) of already estab-
lished infections (Table 2) or cancer (Table 3) where pre-
ventive intervention by vaccine has not effect.
Therapeutic antibodies
The use of intracellular antibodies (intrabodies) to in-
hibit protein function holds promise for the treatment of
human diseases. The difficulties associated with the de-
velopment of intrabody-based therapies are similar to
those that hamper the development of protein inhibitors
in general, and reflect problems in generating reagents
that are effective and specific. This effectiveness and spe-
cificity can be achieved by using intrabodies to combatintracellular parasites like viruses. Indeed, viruses ex-
press proteins that are directly involved in causing dis-
ease and are clearly diverse from those of the host cell.
For viruses that cause only local infections, such as
HPV, the intrabody approach may be more appropriate.
Furthermore, not only the infected cells but also the
transformed cells require the continuous expression of
some HPV proteins, particularly the oncogenes E6 and
E7. This is most evident in Hela cells, derived from an
HPV-associated malignancy in the 1950s, which still al-
most 50 years later require the expression of these onco-
genes for their growth in tissue culture [35,36].
Intrabodies against the E6 [37] and E7 [38] of HPV have
been produced and proved effective in in vitro cancer cell
models. More recently, an intrabody against the E7 of
HPV 16 was proved to block tumor growth in animal
models [39]. Given the accessibility of HPV-associated
lesions to topical therapy, preclinical results suggest that
large interfering molecules, such as intrabodies, may be
useful inhibitors of viral protein–protein interactions and
particularly appropriate for the treatment of HPV-asso-
ciated diseases. However, no clinical study has been pub-
lished so far.
Instead of using intrabodies, the utilization of mono-
clonal antibodies against membrane-expressed antigens
is suggested, that may be induced by the HPV, i.e. Epi-
dermal Growth Factor Receptor (EGFR). Monoclonal
antibodies anti EGFR are already in clinical use and
have been fully reviewed elsewhere [32]. However, be-
side HPV induction other membrane-associated anti-
gens can be found in transformed cervical cells and may
be targeted by monoclonal antibodies. An example of
these antibodies is the adecatumum (MT201), a hu-
manized monoclonal antibody targeting epithelial cell
adhesion molecules, showing activity in cervical can-
cer cell lines over-expressing epithelial cell adhesion
molecule (EpCAM) [40]. This activity may suggest a
hypothetical clinical employment of this monoclonal
Table 2 Clinical trials for HPV-associated pre-neoplastic lesions
Vaccine Antigen(s) Phase Lesions
ADXS11-001: HPV-16 E7 II CIN 2/3, VIN 3, VAIN 2
Lm secreting fusion/LLO-HPV-16 E7 protein (Lm-LLO-E7)
Procervix: adenylate cyclase protein vector delivering HPV16
and HPV18 E7 antigens




MVA E2: Recombinant Modified Vaccinia Ankara (MVA) encoding
E2 from BPV
Bovine Papillomavirus E2 I/II CIN1-3
I/II Male flat condyloma
II High-grade CIN
TG4001/R3484: HPV-16 E6/E7 IIa CIN2/3
Recombinant MVA expressing E6-E7of HPV-16, and IL-2 IIb
Peptides: HPV E7 (aa 12–20) plus E7 lipopetide (PADRE helper peptide,
linker peptide, and E7 peptide: aa 86–93) & Montanide ISA-51 adjuvant




HPV-16 E6/ E7 fusion protein plus ISCOMATRIX adjuvant HPV-16 E6 and E7
I
CIN 1–3, HPV-associated AIN in
HIV-positive male
PD-E7: Modified HPV-16 E7/Hib protein D fusion protein &
AS02B adjuvant
HPV-16 E7
I/II CIN 1, CIN 3
SGN-00101: HPV-16 E7/M. bovis, Hsp65 fusion protein HPV-16 E7 I/II Anal HSIL
I/II High-grade AIN
II
ASCUS and LSIL, recurrent
respiratory papillomatosis,
high-grade CIN
SGN-00101 in poly ICLC adjuvant HPV-16 E7 I CIN 1-3




High-grade AIN in males,
CIN 2/3
ZYC101a: Recombinant HPV-16 and HPV 18 E6-E7 DNA Plasmid
encapsulated in poly microparticles
HPV-16 and HPV-18 E6 and E7
II/III High grade CIN
pNGVL4a-Sig/E7/Hsp70: DNA plasmid expressing mutated HPV-16
E7 fused to Sig and Hsp70
HPV-16 E7
I CIN 2/3




VGX-3100: DNA plasmid expressing HPV-16 and HPV-18 E6 and
E7 proteins
HPV-16 and HPV-18 E6 and E7
I
CIN 2/3 (after surgery or
fourth dose)
II CIN 2/3




HPV-16 and HPV-18 E6 and E7 and
HPV-16 L2
II CIN 2/3
pNGVL4a-Sig/E7 /Hsp70 and TA-HPV prime/boost plus TLR
agonist imiquimod
HPV-16 and HPV-18 E6 and E7 II CIN 2/3
Note: Abbreviations are as in the text.
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clonal antibodies against EGFR.
Therapeutic vaccines
Therapeutic vaccines aim to eradicate or reduce already
infected cells by stimulating cytotoxic T cells against target
infected cells and up-regulating MHC Class I expression.
Vaccine-mediated immune strategies could be directed
toward at least two different stages of the oncogenicinfection: firstly, infection and then secondly, the estab-
lished infection. By eliciting neutralizing antibody responses
the prophylactic vaccines challenge the first infection by
inhibiting the HPV to bind to the cell or the early phases of
viral entry. These vaccines are already in clinical use and
will not be discussed in this review.
The therapeutic vaccines should fight already infected
cells, and could be tailored based on the presence of epi-
somal replicating virus or integrated viral sequences. In
Table 3 Clinical trials for HPV-associated cancer
Vaccine Antigen(s) Phase Cancer
ADXS11-001: HPV-16 I Cervical cancer
Lm secreting fusion to LLO-HPV-16 E7 protein (Lm-LLO-E7) E7 I HPV- oropharyngeal cancer
II Recurrent cervical carcinoma
TA-HPV: Recombinant vaccinia virus expressing E6 and E7 from
both HPV-16 and HPV-18
E6 and E7 of HPV16 and
HPV-18 E6
I Stage Ib and IIa cervical cancer
I/II Advanced cervical cancer
II Stage Ib and IIa cervical cancer
PADRE peptide linked to E7 Lipopeptide HPV-16 E7 I Cervical cancer
HPV-16 E7 epitopes emulsified in Montanide ISA-51 adjuvant HPV-16 E7 I/II Cervical cancer
13 overlapping long peptides covering whole E6 and E7
sequences of HPV 16 plus Montanide ISA-51 adjuvant
HPV-16 E6 and E7 I Advanced cervical cancer stage Ib1
cervical cancer
II
DC pulsed with HPV-16 E7 HPV-16 E7 I Recurrent cervical cancer
pNGVL4a-Sig/E7/Hsp70: DNA plasmid expressing mutated
HPV-16 E7 fused to Sig and Hsp70
HPV-16 E7 I Advanced HNSCC
Note: Abbreviations are as in the text.
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proteins, in the second case only the E6-E7 proteins
appear to be a realistic target of intervention [41]. In
addition, as HPV 16 accounts for over 50% of invasive
cancer worldwide, the clinical studies mainly focused on
the E6 and E7 proteins of this HPV [2].
In the experimental model an effective immunotherapy
administered before tumor challenge includes an antigen-
specific component, whereas an effective immunothe-
rapy after tumor challenge can be achieved through the
enhancement of either innate or adaptive immunity, and
seems to be optimal with both. Therefore, valid thera-
peutic vaccines must achieve this goal. Trials of immuno-
therapy in patients with HPV associated pre-malignancy
are expected to be more effective than in cancer patients,
since the impaired antigen presentation by cervical cancer
cells due to mutations in MHC and TAP genes may ren-
der the immunotherapy less effective. Although there are
potential immune-evasive mechanisms that are attribut-
able to the HPV infection itself [42].
Examples of those therapeutic vaccines, which have
reached phases I and II clinical trials, are presented in
the subsequent paragraphs according to the different
formulations.
Protein/peptide-based vaccines
To date, several protein or peptide-based vaccines are
either undergoing clinical evaluation or are in develop-
ment. A major limitation to peptide-based vaccines is
the HLA restriction that can be overcome by the use of
whole protein-based vaccines, which harbor multiple
immunogenic epitopes, binding various allelic HLA mo-
lecules. On the other hand, protein-based vaccines are
generating predominantly antibody responses ratherthan CTL responses because proteins are processed
through the endocytic/MHC class II pathway. In addition,
both peptides and proteins are poorly immunogenic.
Therefore, most of the research in this area was focused
on the co-administration of adjuvant immune-enhancing
agents such as chemokines, cytokines, and co-stimulatory
molecules to enhance the potency of the vaccine. In par-
ticular saponin-based [43] or liposome–based (LPD) for-
mulations [44], or TLR agonists [45] were employed as
adjuvants for protein vaccines. Recently, the fusion of the
beta-1,3-1,4-glucanase (LicKM) of Clostridium thermocel-
lum bacterial protein to the HPV E7 protein produced an
antigen with strong intrinsic adjuvating activity, indicating
that this manipulation of the antigen may elicit some un-
known helpful functions [46,47]. Many other fusion pro-
teins were reported to elicit some adjuvating activities
such as Mycobacteria-derived heat-shock proteins (Hsp)
[48,49], truncated Pseudomonas aeruginosa exotoxin A
[50], Bordetella pertussis adenylate cyclase [51], and the
cell penetrating peptide Limulus polyphemus protein [52].
In addition, alternative delivery system such as electropo-
ration can further improve the activity of this adjuvating
protein vaccine [45].
Peptide-based vaccines need to increase not only the
poor immunogenicity level but also the obstacle of MHC
restriction. TLR agonists have also been explored as adju-
vants for peptide-based HPV vaccines because of their
capability to activate both innate and adaptive immunity.
Vaccines consisting in CTL and or TH epitope adjuvated
with TLR 9 [53], TLR4 or [54] and TLR3 [55] agonists
demonstrated their efficacy in mouse models. This activity
was demonstrated also by utilizing a CTL epitope fused to
a T-helper epitope, pan-DR epitope (PADRE) [56]. These
results suggest that adjuvants targeting dendritic cells are
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(TriVax) based on the administration of co-stimulatory
anti-CD40 monoclonal, TLR agonist Polyinosinic-polycy-
tidylic acid [Poly(I:C)] and CD8+ T-cell epitope HPV 16
E7 (aa49-57) was able to induce tumor clearance in two
HPV-induced murine cancer models [57]. Many of these
protein/peptide-based vaccines moved to clinical trials
where all of them indicated low toxicity and a good safety
profile, but a strong discordance exists between immune
and clinical responses, reinforcing the need of further im-
provement to the vaccination.
However, among the protein-based vaccine candidates,
SGN-00101 vaccine, a fusion protein consisting of Hsp
from Mycobacterium bovis and HPV 16 E7, has gene-
rated considerable interest. As a single-agent therapy, in
both phase I and phase II clinical trials, fusion protein
was able to induce regression of lesions in anal high-
grade squamous intraepithelial lesions [58], recurrent re-
spiratory papillomatosis [59], and CIN 2-3 [60-62]. In
addition, phase II clinical trial with TA-CIN, a fusion
protein-based vaccine expressing HPV 16 L2-E6-E7 con-
jugated proteins, in conjunction with topical application
of TLR agonist Imiquimod, an imidazoquinoline amine,
showed high levels of CD4+ and CD8+ T cells locally in
patients with high-grade vulvar intra-epithelial neoplasia
(VIN) [63]. One year after treatment 63% patients
showed complete clinical regression of VIN lesions, as-
sociated with HPV clearance in 36% of the subjects.
More recently Genticel’s vaccine candidate Procervix
utilizing the adenylate cyclase (cyaa) technology, a pro-
tein vector that delivers the E7 antigens from HPV 16
and HPV 18 was proved safe in phase I trial. The com-
pany is now (March 2014) launching its phase II trial in
women infected with high-risk HPV before the appear-
ance of high- grade cervical lesions. This trial is the first
ever recruiting HPV infected women with no cervical le-
sions and it would give information about a vaccine that
may close the gap between preventive vaccines and later
stage therapeutic options [64].
Since peptide-based vaccines are stable, easy to pro-
duce and have a high safety profile, many clinical trials
have been reported. Research has focused on addressing
the main limitations of peptide-based vaccines, namely
their low immunogenicity, and the enhancement of the
immunogenicity of peptide-based vaccines has been ex-
plored in clinical studies. The PADRE universal T-helper
peptide was utilized to increase the activity of CTL epi-
topes encoding HPV 16 E7 that was presented by HLA-
A*0201 (50% of the general population). These vaccines
failed to mount a valid immune response in women with
late stage cervical cancer [65,66]. More promising results
were obtained in HLA-A2-positive patients with CIN/
VIN 2/3 [67], where HPV E7 lipopeptide (aa 86-93)/
PADRE was able to stimulate an immune response andled to complete regression of CIN lesions in 3 of 17
valuable patients. However, these vaccines presented
limitations due to the HLA restriction. Therefore, this
limitation was avoided by using long peptide which
prompted their utilization in clinical trials. In cervical
cancer patients who had undergone resection, the use of
immunization with 13 overlapping long peptides span-
ning the entire sequence of HPV 16 E6 and E7 mixed
with Montanide ISA 51 clearly revealed immunization-
driven IFN-gamma production in enzyme-linked immu-
nospot (ELISPOT) assay after completing the protocol
[68]. When this same platform was tested in immunizing
cervical cancer patients with active disease, both CD4+
and CD8+ T-cell IFN-gamma responses were detected
toward both antigens [69]. Moreover, significant in-
creases in proliferative capacity were also noted in
responding T cells, reminiscent of the type of response
noted in spontaneous regression [69]. This vaccine was
well tolerated with few side effects: minor swelling at the
injection site and flu-like symptoms. Phase II clinical tri-
als of this vaccine in histologically confirmed HPV 16-
positive high-grade VIN patients had a complete regres-
sion of their lesion after 3 or 4 vaccinations with HPV
16 E6/E7 overlapping peptide vaccine [70]. In the non-
responders to the vaccine, an increased number of HPV
16-specific CD4 + CD25 + Foxp3+ Treg cells was ascer-
tained [71].
The presence of these Foxp3+ T cells is linked to im-
paired immunity in malignancies. The efficacy of this
vaccine was also demonstrated in a placebo-controlled
randomized Phase II study showing an increased num-
ber of HPV 16-specific T cells in patients with HPV 16+
high squamous intraepithelial lesion (HSIL) [72].
Plant-derived/produced vaccines
Plant molecular pharming represents a well-established
biotechnology area that includes the production of pro-
tein biopharmaceuticals such as enzymes, hormones,
antibodies, and vaccine antigens in plant systems. Plant-
produced proteins represent a significant fraction of
pharmaceuticals in advanced preclinical and clinical trial
status. However, plant platforms present several draw-
backs: time-consuming in generating stable transgenic
lines, non homogeneous protein production in different
tissues, impact of pests and diseases even in controlled
conditions (greenhouses) and, more importantly, growth
in non-sterile conditions. This last point may affect the
good manufacturing practices (GMP) necessary for the
production of pharmaceuticals. Transient expression or
in vitro culture have emerged as alternative platforms to
circumvent some of these drawbacks. Food and Drug
Administration (FDA) has recently approved the first
plant-made drug for human use, an enzyme produced in
genetically engineered carrot cells for treating type 1
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lactic and therapeutic HPV vaccines is proven, with evi-
dence of efficacy in animals. There are data showing that
an adjuvant-like effect was obtained in immunizations
with crude tobacco plant extracts containing the E7 pro-
tein of HPV 16 [73,74]. The recombinant plant-derived
vaccines as ‘in planta formulation’ without adjuvants
were able to elicit also a protective Th1 cell response in
mice. Similar adjuvating activity was seen in another to-
bacco plant-produced fusion protein of the HPV 16 E7;
this antigen preparation was able to induce a specific
CD8+ T stimulation that elicited a therapeutic effect on
experimental tumors [46,47]. Finally, the possibility to
produce E7 with high immunological activity in microal-
gae opens the way to producing antigens at affordable
price, retaining the adjuvating activity of these plant-
derived antigens [75]. An FDA-approved clinical trial for
non-Hodgkin’s lymphoma with plant-produced single-
chain variable fragment (scFv) was able to establish the
safety and immunogenicity of plant made human vac-
cines [76,77], thus indicating the feasibility of this ap-
proach for human anticancer therapies. However, to our
knowledge, no clinical trial with plant derived anti-HPV
vaccine has been carried out yet.
DNA/RNA based vaccines
DNA vaccines have been used in the clinical arena to
elicit antigen-specific immune responses. Although nu-
cleic acid vaccines do not appear to induce as vigorous
immune responses as live viral vaccine vectors, they
have several advantages, mainly naked DNA is relatively
safe, stable, cost efficient, and able to sustain reasonable
levels of antigen expression within cells. DNA-based
plasmid vectors remain stable in a wide range of condi-
tions over great lengths of time (longer periods than
RNA vaccines), and they can be delivered with little risk
to individuals who are immunosuppressed. In addition,
since DNA vaccines do not elicit neutralizing antibodies
in the vaccinated patient, they can be repeatedly admin-
istered with similar efficacy. Many strategies have been
employed to produce an efficient delivery of targeted
antigen-to-antigen presenting cells (APC) such as den-
dritic cells (DCs), an enhancement of antigen processing
and presentation in DCs, and an augmentation of DC
and T cell interaction [78]. Recently, it has been reported
that the fusion of the E7 gene of HPV 16 with a plant
virus coat protein produced strong antitumor activity in
a mouse model activating both CD4+ and CD8+ T cells
[46,79], as well as a fusion of E7 gene to a gene encoding
a mutated form of the immunotoxin from saponaria offi-
cinalis, the saporine [80]. The latter should enhance the
activity of the vaccine by the immunomodulant activity
of this mutated saporine that has lost its toxic activity.
The possibility to utilize enhanced delivery methods likeelectroporation, microencapsulation, and gene gun has
further enhanced the targeting of DNA vaccine to DCs.
A dose-escalation trial of plasmid DNA encoding a
transgene that produced E7 linked to Hsp70 showed
limited efficacy at the highest dose, with low induction
of responses in the IFN-gamma ELISPOT assay and a
resolution rate of 33% [81].
A plasmid DNA encoding a 13-amino acid sequence
of E7 encapsulated in biodegradable poly (D,L-lactide-
co-glycolide) micro-particles was utilized to develop the
ZYC101 vaccine expressing a HPV 16 E7 HLA-A2 re-
stricted peptide. Two different phase I clinical trials
examining the potential treatment of patients with anal
dysplasia or with high-grade CIN, respectively, demon-
strated a high number of immunological response i.e.
circulating HPV-specific T cells and histological regres-
sion/improvement in 1/3 of the patients [82,83]. The im-
proved version ZYC101a, that includes in addition to
the HPV-encoding sequences of HPV 16 E7 the regions
encoding segments of HPV 16 and HPV 18 E6 and E7
viral proteins, is one of the few therapeutic vaccines
reaching the phase II/III in clinical trials involving sub-
jects with high-grade CIN. In a prospectively defined
population of women younger than 25 years CIN reso-
lution was significantly higher in the ZYC101a groups
compared to placebo [84]. Its activity in the treatment of
patients with CIN 2/3 was also evaluated in a double-
blinded, randomized, placebo-controlled clinical trial
where half of 21 patients receiving the vaccine showed
HPV 16/18-specific T cell responses but only 6 patients
recovered from the high grade CIN [85].
VGX-3100, a DNA vaccine incorporating plasmids tar-
geting HPV 16 and 18 E6 and E7 proteins was utilized
in clinical trials employing electroporation technology.
This technology was demonstrated particularly effective
in animal models where the candidate vaccine is deliv-
ered via intramuscular injection followed by electropor-
ation using various devices to deliver a small electrical
charge. In a phase I clinical trial, 78% of the VGX-3100
vaccinated high-grade CIN subjects showed T cell and
antibody responses [86]. On the bases of these find-
ings, a double-blinded, randomized, placebo-controlled
phase II clinical trial is ongoing on high grade CIN
(NCT01304524). Further trials will be developed associ-
ating this vaccination with IL-12, used as an adjuvant, in
order to significantly increase the CD4+ T cell response
and with a vaccination against telomerase (hTERT), an
antigen that is known to be related to a great number of
human tumors and whose immunogenicity was demon-
strated by the presence of existing naturally occurring T
cell responses (Bagarazzi M. Personal Communication).
Other DNA vaccines have also been associated with
other adjuvating treatments. In particular, the TLR7
agonist, Imiquimod promoting the activation of antigen-
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of cytokines IFN-alpha, IL-6, and TNF alpha [87] was
shown to be active in mouse models [88]. In particular,
the Imiquimod treatment affected the tumor microenvir-
onment by reducing the number of myeloid-derived sup-
pressor cells that have an immunosuppressive role and
increasing natural killer (NK) and NKT cells that may
play a role in tumor volume reduction. Thus this ap-
proach was utilized in an ongoing phase I clinical trial,
which investigates a prime-boost strategy, combined
with topical Imiquimod in treating patients with CIN3.
The prime-boost strategy consisted of a DNA vaccine
encoding an endoplasmic reticulum signal sequence
(Sig), linked to an attenuated form of HPV 16 E7 fu-
sed to Hsp70 (pNGVL4a-Sig/E7(Detox)/Hsp70) boosted
with a recombinant vaccinia virus encoding E6 and E7
of HPV 16 and 18 (TA-HPV) [NCT00788164].
Finally, the use of RNA replicons is a potentially inter-
esting strategy for HPV vaccination. RNA replicons are
naked RNA molecules derived from alpha-viruses, such
as Sindbis virus [89,90], Semliki Forest virus [91-93], and
Venezuelan equine encephalitis (VEE) [94] viurs. These
RNA vaccines are self-replicating and self-limiting, and
may be administered as either RNA or DNA, which is
then transcribed into RNA replicons. RNA replicon-
based vectors can replicate in a wide range of cell types
and can be used to produce sustained levels of antigen
expression in cells, making them more immunogenic
than conventional DNA vaccines. However, RNA repli-
cons are less stable than DNA. To combine the benefits
of DNA and RNA replicon, DNA-launched RNA repli-
con, termed ‘suicidal’ DNA was utilized for HPV vaccine
development in preclinical models [94,95].
This ‘suicidal DNA’ is transcribed into RNA within the
transfected cell and provides a stable and efficient way
to express tumor antigen but the cells may undergo
apoptosis. Another replicon system is derived from the
flavivirus Kunjin (KUN) [96]. The new generation of
KUN replicon vectors, which allows for the synthesis of
replicon RNA from plasmid DNA did not induce cellu-
lar apoptosis and was able to elicit specific T cell re-
sponses protecting mice from tumor challenge [97].
However, despite the general success of RNA replicons
in preclinical models, RNA replicon-based vaccines have
had limited clinical testing.
The newest mRNA-based vaccines have also been de-
veloped by Novartis as a non-viral delivery system for
self-amplifying RNA that has been successfully tested in
preclinical models. Another mRNA-based vaccine is the
RNActiveW vaccine platform from CureVac (Tübingen,
Germany) that is based on a more stable modified
mRNA sequence with increased immunogenicity by
complexation with protamine. This mRNA vaccine ex-
ploits both the antigenic and the adjuvant properties ofmRNAs to activate the adaptive and innate immune sys-
tem. Two ongoing clinical trials on patients with pros-
tate and non-small cell lung cancer show that
RNActiveW vaccines are safe and effective in inducing
long lasting, humoral and cellular immune responses.
No information is available on the possible utilization on
HPV-associated cancers.
Bacterial/viral vectors
Bacteria, such as Listeria monocytogenes (LM) [98,99],
Lactococcus lactis [100], Lactobacillus casei [101],
Salmonella and Bacillus Calmette-Guerin, and several
viral vectors, including vaccinia virus (VV), adenovirus,
adeno-associated virus, alpha-virus, and its derivative
vectors, have been used to deliver genes or proteins
of interest to elicit antigen-specific immunotherapy.
Among the bacterial vectors, LM has emerged as a
promising vector, because in animal models it is able to
induce both CD8+ and CD4+ immune responses, to
elicit regression of established tumors, and to overcome
central tolerance by expanding low avidity CD8+ T cells
specific for E7 [98]. ADXS11-001 a live, attenuated LM
bacterial vector secreting HPV 16 E7 fused to listerioly-
sin O (LLO) LLO was utilized in clinical trials. Promis-
ing results of this vaccine in phase I trials for safety
and immunological responses [102,103] were further
assessed in phase II clinical trials. At least three trials
are ongoing involving women with persistent or recur-
rent cervical carcinoma (NCT01266460), with CIN 2/3
with surgical indication (NCT01116245) [104], and pa-
tients (including male) with HPV-associated oropharyn-
geal cancer (NCT01598792).
Among viral vectors employed for the expression of
HPV antigens, like adenoviruses [105,106], alpha-viruses
[107-109] and VV [110-112], the last virus was historic-
ally one of the first viral vectors employed in clinical tri-
als on therapeutic vaccines against HPV-associated
cancer [113]. More recently Avipox viruses have been
developed as novel vectors for the development of vac-
cines. Although their replication is restricted to avian
they are permissive for entry and transgenic expression
in most mammalian cells, and immunologically non
cross-reactive with vaccinia, which avoids pre-existing
immunity in smallpox experienced humans. Avipox vi-
ruses might therefore represent safer immunogens that
have demonstrated their activity in inhibiting the growth
of HPV16 E7 expressing tumor in C57 Bl6 mice with a
HPV16 E7 DNA-prime/Fowlpox HPV16 E7-boost
schedule [114].
To date many VV vaccines have been employed in
clinical trials to deliver genes and antigens of interest ef-
ficiently. Phase I/II clinical trials in patients with vulvar
or vaginal and early or late -stage cervical cancer were
conducted with a vaccinia vector encoding HPV 16 and
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[113,115-117]. In particular, in a phase II clinical trial, 29
patients with stage I or II cervical cancer were vacci-
nated twice via scarification with TA-HPV; although
clinical outcomes were not measured due to surgical
intervention in all patients, induction of CTL responses
were detected in a number of patients in the form of tar-
get cell lysis by isolated peripheral bone marrow cells
(PBMCs) [117].
In another study, a recombinant VV expressing E6 and
E7 antigen together with IL-2 (TG4001/R3484) was ad-
ministered to CIN 2/3 patients, with very promising clin-
ical results. Ten patients (48%) were evaluated as clinical
responders at month 6. At month 12, 7 out of 8 patients
without conization reported neither suspicion of CIN 2/3
relapse nor HPV 16 infection [118]. Interim results phase
IIb trial on patients with HPV-related CIN 2/3 lesions
demonstrated the activity of vaccine in monotherapy, but
the trial did not reach its primary endpoint of six-month
resolution of CIN 2/3 and will not move on to a phase III
trial [119]. A recombinant modified vaccinia Ankara vec-
tor was also utilized to express papillomavirus protein
other than E6 or E7, namely the bovine papillomavirus E2
(MVA-E2). E2 is a transcriptional repressor of E6 and E7
oncogenes, it was assumed that in low grade lesions,
where the virus is not integrated, the MVA-E2 expressed
protein could bind to the repressor region of the viral gen-
ome. However, there is no evidence for E2 expression dir-
ect contribution to the therapeutic effect seen in both
patients with CIN [120,121] and genital warts [122]. The
vaccine could be active such as a non-specific “pro-inflam-
matory stimulation” in the cervico-vaginal tract that in-
duces an immune response.
Finally, in alternative to viral vectors, synthetic viral
vector like virus like particle (VLP) can be utilized be-
cause they are easy to manufacture and have the cap-
acity for compacting DNA, and targeting specific cell
receptors. Thus, the same technology used for producing
anti-HPV prophylactic vaccines was employed for pro-
ducing chimeric VLPs. An L1–E7 fusion protein has
been shown to self-assemble into chimeric VLPs (CVLP)
that can induce E7-specific cellular immunity in mice
[123]. A randomized, double blind, placebo-controlled
clinical trial has been conducted in CIN 2/3 patients
with CVLP. Antibodies with high titers against HPV
16 L1 and low titers against HPV 16 E7 as well as cellu-
lar immune responses against both proteins were in-
duced. Although not statistically significant a trend for
histological improvement to CIN I or normal histology
was seen in 39% of the patients [124].
Dendritic cells (DCs) based vaccines
The immune response to initial stages of infection causes
inflammatory responses that trigger innate effector cells,such as NK and NKT cells. This inflammatory response,
driving the innate immunity, is initiated through
pathogen-associated molecular pattern (PAMP) sensors
including TLRs 1–9. These receptors in response to spe-
cific bacterial or viral components activate APCs via the
transcription factor nuclear factor KB (NF-KB). In
addition, infection may alter the local metabolic and
cellular microenvironment activating danger-associated
molecular pattern (DAMP) sensors, particularly nucleotide-
binding oligomerization domain (NOD)-like receptors
(NLRs), as components of multiprotein complexes termed
the inflammasomes, inducing maturation and releasing
members of the IL-1 family. In particular, the produced IL-
1b and IL-18 mediate repair responses such as angiogenesis
and, via upregulation of cytokines and chemokines, induce
the recruitment of inflammatory cells to the site of infec-
tion. The observed slow clearance of HPV infection and
weak immune responses to viral proteins is a likely conse-
quence of the nonlytic nature of HPV infection and a con-
sequent delay in induction of PAMP- and DAMP-induced
inflammatory responses through TLRs and the inflamma-
somes. Thus, in the absence of inflammation a number of
events take place (i.e. IL-10 production by Th cells and
mast cells; IFN-gamma production by CD-1d-activated
NKT cells, increased TGF-beta) inducing negative regula-
tory signals that in turn can change the state of the APC by
altering costimulatory molecule expression, thus inhibiting
induction of cytotoxic effector T cells. Therefore a therapy
aimed to reactivate these APCs could be a valid tool for
clinical intervention.
Among specialized APCs the most potent are DCs, be-
cause they express high levels of MHC and co-
stimulatory molecules. Therefore, DCs were the research
focus of many investigators and a variety of methods for
generating DCs, loading them with tumor antigens, and
administering them to patients. The success of Provenge,
a DC vaccine incorporating prostatic acid phosphatase,
in patients with advanced prostate cancer has generated
great interest for DC-based vaccines [125,126]. Although
expensive, DC-based vaccines have been tested in pa-
tients with HPV-associated cervical cancer by success-
fully transducing genes coding for E6 and E7 into DCs.
In a clinical study, autologous DCs were pulsed with
HPV 16 or HPV 18 E7 recombinant proteins and E7-
specific CD8+ T cell responses were observed in 4 out of
11 late stage cervical cancer patients [127]. In another
clinical study, stage IB or IIA cervical cancer patients
were vaccinated with autologous DC pulsed with recom-
binant HPV 16/18 E7 antigens and keyhole limpet
hemocyanin 1 (KLH), an immunological carrier protein.
This vaccine generated E7-specific T cell responses in 8
out of 10 patients and antibody responses in all patients
[128]. Another ongoing clinical trial is being conducted
in Taiwan National University in recurrent cervical
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E7 antigen. However, DC-based vaccines could be used
to treat advanced cervical cancers but are unlikely to be
used to treat CIN lesions because the procedures in-
volved in this kind of treatment are expensive and labor-
intensive.
Combinational immunotherapy
Given the importance of local microenvironment in the
persistence of HPV lesions, strategies aiming to alter
local immunity have shown some positive results, there-
fore therapeutic HPV vaccine strategies have shifted to-
ward combinatorial approaches with radiotherapy and
chemotherapy. Low-dose radiation in combination with
HPV vaccination was effective in the treatment of tu-
mors in preclinical models [129]. Radiation therapy
seems to be a useful method in stabilizing tumor cell
growth when applied with immunotherapy by inducing
apoptosis in tumor cells.
A chemotherapeutic agent in combination with DNA-
based vaccines was proven an effective HPV therapy in
preclinical models [130-136]. Low cyclophosphamide
doses, altering local immunity, exerted some positive ef-
fects in persistent low-risk HPV lesions [135]. A ran-
domized trial comparing chemotherapy versus a
combination with the HPV 16 Synthetic Long Peptide
(SLP) in advanced cervical cancer is planned. A pilot
study is ongoing with the aim to investigate the optimal
time (“window”) for the vaccination with the HPV 16
SLP vaccine after standard treatment of 6 cycles
Carboplatin-Paclitaxel every three weeks (EudraCT2010-
018841-76).
A randomized study was carried out in 110 recurrent/
refractory cervical cancer patients with cisplatin and dif-
ferent doses of HPV bacterial vector-based vaccine
ADXS11-001, and preliminary results showed efficacy
and manageable toxicity [137].
In addition, other compounds affecting the immuno-
logical environment like COX-2 inhibitors, through the
prevention of the production of prostaglandin E2 or
antibodies to IL-6 [138] or IL-10 [139] or the TLR agon-
ist Imiquimod could be effective.
In particular, Imiquimod is already in clinical use against
warts stimulating local innate immunity and potentiating
adaptive immune response by activating tissue antigen
presenting cells. A number of studies with topical Imiqui-
mod have been reported with favorable results mainly in
vulvar intraepithelial neoplasia (VIN) lesions [63,140] and
combination therapy with HPV DNA vaccines described
in the previous paragraphs of this review.
Cytokines-based therapies in combination with HPV
therapeutic vaccine showed promising results in preclin-
ical models. Treatment with IL-12 gene, administered as
gene therapy, viral gene therapy, by adenovirus, and incombination with E6-E7 oncogenes, determined tumor
growth suppression [141,142].
Recently, programmed death-1 receptor (PD-1) is
emerging as a pivotal target for combination therapy by
affecting immune suppression.
Indeed, PD-1 is expressed on T cells following T-cell re-
ceptor (TCR) activation and binding of this receptor to its
cognate ligands, programmed death ligand (PDL)-1 and
PDL-2, down-regulates TCR signals, promoting T-cell an-
ergy and apoptosis, thus leading to immune suppression.
An anti-PD-1 antibody (CT-011) with Treg-cell deple-
tion by low-dose cyclophosphamide (CPM), combined
with HPV 16 E7 peptide vaccine, produced synergistic
antigen-specific immune responses inducing complete
regression of established tumors in a significant percent-
age of treated animals, with prolonging survival [143].
Expanded phase I clinical studies with anti-PD-1
(BMS-936558) and anti-PDL -1 (BMS-936559) showed
objective clinical responses in renal cell carcinoma, mel-
anoma, and non–small cell lung cancer, and a relation-
ship between tumor cell surface PD-L1 expression and
objective responses to anti-PD1 therapy [144,145]. In
addition, a recent study showed that PD-1: PDL-1 path-
way may create an “immune-privileged” site for initial
viral infection in the tonsils and subsequent adaptive im-
mune resistance once tumors are established suggesting
a rationale for therapeutic blockade of this pathway in
patients with HPV + oropharyngeal squamous cell car-
cinoma [146]. Other strategies trying to inhibit the sup-
pressive tumor microenvironment utilize monoclonal
antibodies such as Ipilimumab. This antibody is a fully
human monoclonal antibody against the cytotoxic T-
lymphocyte antigen-4 (CTLA-4), an immune-inhibitory
molecule expressed in activated T cells and in suppres-
sor T regulatory cells. The interaction between the
monoclonal antibody and CTLA-4 blocks inhibitory sig-
nals and enhances T cell activation, leading to increased
antitumor responses [147]. Ipilimumab has been ap-
proved for melanoma, but ongoing trials are testing the
drug in other tumors, among them locally advanced cer-
vical cancer, in a sequential regimen following chemora-
diation (NCT01711515).
Conclusions
The development of cervical cancer depends not only on
efficient negative regulation of cell-cycle control sup-
porting the accumulation of genetic damage, but also on
a sophisticated viral mechanism of immune evasion
[20-22]. Despite this complex interplay, most HPV infec-
tions are cleared within one year, and cell-mediated im-
munity plays an important role in this process. Thus, a
better understanding of immunological path involved in
cervical cancer carcinogenesis is an important goal in
cervical cancer knowledge, and the development of new
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resent an innovative strategy in this complex disease. Al-
though antigen-specific immunotherapy induced by
therapeutic HPV vaccines was proved extremely effica-
cious in preclinical models, its progression through clin-
ical trials suffered of the early poor responses. Such
initial clinical trials were conducted in advanced cancer
patients to evaluate the safety of the respective vaccine.
Because of the immunosuppressive milieu generated by
established tumors, it appears that (likewise to cancer
immunotherapy in general) in cases of advanced disease,
an immunological antitumor effect will, if at all, only be
successful along with standard therapy. Later attempts
took advantage of the unique situation in HPV-related
carcinogenesis, that is, the existence of well-defined pre-
cursors to cervical, anal or vulvar cancer.
Several clinical studies on these precursors lesions
have so far been completed with promising effects, even
if these trials were not powered to detect small effects in
the vaccine versus the placebo groups. Indeed, there was
no follow-up study with the same strategy, perhaps as a
result that these trials were investigator-initiated or
sponsored by small biotech companies.
Large pharmaceutical corporations that could have en-
sured continuation of the individual program and guar-
antee the prosecution in more powered phase II/III
trials were completely lacking. Even the partnership an-
nounced in 2007 between a large pharmaceutical firm
(Roche) and a biotech company (Transgene) on a prom-
ising vaccine TG4001 was recently discontinued.
In conclusion immune escape and immune suppres-
sion are active in cancer and to some extent also in pre-
malignant lesions and, therefore one might consider
targeting persistent infections before they become clinic-
ally apparent. This ‘paradigm shift’ in vaccination of can-
cer patients is a quite logical step in HPV-related
cervical cancer. Treating this early condition with post-
exposure prophylaxis might be more successful than
therapy at more advanced stages. Several well-defined
cohorts of women with persistent infections do exist,
and the design and execution of clinical trials aiming to
clear of HPV DNA should be straightforward. However,
it is important to take into consideration that patients
with HSIL are generally asymptomatic and can be
treated by minor surgical procedures. A clinical trial on
long overlapping peptide vaccine in CIN 2/3 patients
was stopped prematurely because motivational problems
of the patients and the local/systemic side effects of the
vaccine. Thus, motivational problems must be taken into
account when considering studies in patients with pre-
malignant lesions for whom an effective treatment is
available [72]. Future developments should consider the
disparities of side effects between standard of care and
new therapies to maximize the potential benefits oftherapeutic vaccination. In addition, therapeutic efficacy
would receive beneficial effects by addressing the im-
munosuppressive tumor microenvironment. Combin-
ational strategies particularly for cancer patients are a
promising tool to control tumor metastasis and elimin-
ate cancer cells altogether.
The development of prophylactic and therapeutic HPV
vaccines must be continued in order to come close to
the eradication of HPV-associated malignancies even in
other localizations [148,149], getting rid of the percep-
tion (after the effectiveness of commercial preventive
vaccines) that the problem has been solved.
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